IL236613A0 - A tri-salt form of metformin - Google Patents
A tri-salt form of metforminInfo
- Publication number
- IL236613A0 IL236613A0 IL236613A IL23661315A IL236613A0 IL 236613 A0 IL236613 A0 IL 236613A0 IL 236613 A IL236613 A IL 236613A IL 23661315 A IL23661315 A IL 23661315A IL 236613 A0 IL236613 A0 IL 236613A0
- Authority
- IL
- Israel
- Prior art keywords
- metformin
- tri
- salt form
- salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C277/00—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C277/08—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups of substituted guanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
- C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261669763P | 2012-07-10 | 2012-07-10 | |
| US201261670376P | 2012-07-11 | 2012-07-11 | |
| US201261670368P | 2012-07-11 | 2012-07-11 | |
| US13/841,970 US8765811B2 (en) | 2012-07-10 | 2013-03-15 | Tri-salt form of metformin |
| PCT/US2013/049984 WO2014011814A1 (en) | 2012-07-10 | 2013-07-10 | Tri-salt form of metformin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL236613A0 true IL236613A0 (en) | 2015-02-26 |
Family
ID=49916541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL236613A IL236613A0 (en) | 2012-07-10 | 2015-01-11 | A tri-salt form of metformin |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2872483A4 (enExample) |
| JP (1) | JP2015523382A (enExample) |
| KR (1) | KR20150036235A (enExample) |
| CN (1) | CN104684889A (enExample) |
| AU (1) | AU2013290168A1 (enExample) |
| BR (1) | BR112015000368A2 (enExample) |
| CA (1) | CA2878819A1 (enExample) |
| IL (1) | IL236613A0 (enExample) |
| IN (1) | IN2015KN00076A (enExample) |
| MX (1) | MX2015000408A (enExample) |
| WO (1) | WO2014011814A1 (enExample) |
| ZA (1) | ZA201500274B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853259B2 (en) * | 2013-02-07 | 2014-10-07 | Banavara L. Mylari | Metformin derivatives for treating diabetes and diabetes complications |
| WO2015171516A1 (en) | 2014-05-05 | 2015-11-12 | Thetis Pharmaceuticals Llc | Compositions and methods relating to ionic salts of peptides |
| CN107074884A (zh) | 2014-06-18 | 2017-08-18 | 西蒂斯制药有限责任公司 | 活性剂的矿物质氨基酸复合物 |
| US20170119841A1 (en) * | 2015-11-04 | 2017-05-04 | Thetis Pharmaceuticals Llc | Amino acid salts of unsaturated fatty acids |
| KR102437682B1 (ko) | 2016-06-03 | 2022-08-29 | 테티스 파마수티컬스 엘엘씨 | 특화된 사전 해소 매개체의 염에 관한 조성물 및 방법 |
| US10471963B2 (en) | 2017-04-07 | 2019-11-12 | TuSimple | System and method for transitioning between an autonomous and manual driving mode based on detection of a drivers capacity to control a vehicle |
| US10737695B2 (en) | 2017-07-01 | 2020-08-11 | Tusimple, Inc. | System and method for adaptive cruise control for low speed following |
| CN113105367B (zh) | 2021-03-30 | 2022-08-02 | 广州大学 | 一类二甲双胍盐及其制备方法和应用 |
| CN114349665B (zh) * | 2021-11-30 | 2023-06-09 | 潍坊博创国际生物医药研究院 | 二甲双胍焦谷氨酸晶体及其制备方法与应用 |
| CN115192625A (zh) * | 2022-06-30 | 2022-10-18 | 山东海赜生物科技有限公司 | 一种口服组合物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2312990C (en) * | 1997-12-08 | 2008-04-29 | Bristol-Myers Squibb Company | Novel salts of metformin and method |
| FR2774591B1 (fr) * | 1998-02-12 | 2000-05-05 | Lipha | Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie |
| WO2002012177A1 (en) * | 2000-08-03 | 2002-02-14 | Igor Anatolievich Pomytkin | Composition of metformin with succinic acid or salts thereof and method for treating diabetes |
| CA2516142A1 (en) * | 2003-03-18 | 2004-09-30 | Novartis Ag | Compositions comprising fatty acids and amino acids |
| EP1591114A1 (en) * | 2004-03-12 | 2005-11-02 | Fournier Laboratories Ireland Limited | Use of metformin and orlistat for the treatment or prevention of obesity |
| JP5292404B2 (ja) * | 2007-09-21 | 2013-09-18 | ハンオル バイオファーマ カンパニー，リミテッド | Ｎ，ｎ−ジメチルイミドジカルボンイミド酸ジアミドのジカルボン酸塩、その製造方法、及びその薬剤学的組成物 |
| WO2009080022A1 (en) * | 2007-12-20 | 2009-07-02 | Fertin Pharma A/S | Compressed chewing gum tablet |
| US20110082119A1 (en) * | 2008-06-13 | 2011-04-07 | Takashi Yano | Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis |
| CN107233337A (zh) * | 2009-04-29 | 2017-10-10 | 阿马里纳药物爱尔兰有限公司 | 含有epa和心血管剂的药物组合物以及使用其的方法 |
| BR112013009635A2 (pt) * | 2010-10-19 | 2016-07-12 | Elcelyx Therapeutics Inc | terapias à base de ligante de receptor quimiossensorial |
| US8796338B2 (en) * | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
| US20120178813A1 (en) * | 2011-01-12 | 2012-07-12 | Thetis Pharmaceuticals Llc | Lipid-lowering antidiabetic agent |
| US8853259B2 (en) * | 2013-02-07 | 2014-10-07 | Banavara L. Mylari | Metformin derivatives for treating diabetes and diabetes complications |
-
2013
- 2013-07-10 BR BR112015000368A patent/BR112015000368A2/pt not_active IP Right Cessation
- 2013-07-10 MX MX2015000408A patent/MX2015000408A/es unknown
- 2013-07-10 KR KR20157002264A patent/KR20150036235A/ko not_active Withdrawn
- 2013-07-10 AU AU2013290168A patent/AU2013290168A1/en not_active Abandoned
- 2013-07-10 CA CA2878819A patent/CA2878819A1/en not_active Abandoned
- 2013-07-10 EP EP13817534.4A patent/EP2872483A4/en not_active Withdrawn
- 2013-07-10 IN IN76KON2015 patent/IN2015KN00076A/en unknown
- 2013-07-10 CN CN201380046842.4A patent/CN104684889A/zh active Pending
- 2013-07-10 JP JP2015521784A patent/JP2015523382A/ja active Pending
- 2013-07-10 WO PCT/US2013/049984 patent/WO2014011814A1/en not_active Ceased
-
2015
- 2015-01-11 IL IL236613A patent/IL236613A0/en unknown
- 2015-01-14 ZA ZA2015/00274A patent/ZA201500274B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201500274B (en) | 2017-10-25 |
| IN2015KN00076A (enExample) | 2015-07-31 |
| JP2015523382A (ja) | 2015-08-13 |
| CA2878819A1 (en) | 2014-01-16 |
| KR20150036235A (ko) | 2015-04-07 |
| BR112015000368A2 (pt) | 2017-06-27 |
| EP2872483A4 (en) | 2016-03-16 |
| CN104684889A (zh) | 2015-06-03 |
| EP2872483A1 (en) | 2015-05-20 |
| WO2014011814A1 (en) | 2014-01-16 |
| MX2015000408A (es) | 2015-07-14 |
| AU2013290168A1 (en) | 2015-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL238578B (en) | Spliceostatin analogs | |
| AU347535S (en) | Bracelet | |
| GB201207406D0 (en) | Novel compounds | |
| ZA201500274B (en) | Tri-salt form of metformin | |
| IL238800A0 (en) | new compounds | |
| GB201212871D0 (en) | Novel compounds | |
| GB201209986D0 (en) | Novel compounds | |
| IL280595A (en) | new compounds | |
| GB201222711D0 (en) | Novel compounds | |
| GB201501016D0 (en) | Preparation of 18F-fluciclovine | |
| GB201207392D0 (en) | Novel compounds | |
| GB201209670D0 (en) | Novel compounds | |
| GB201212816D0 (en) | Novel compounds | |
| GB201204590D0 (en) | Prodrugs of thiazolamine compounds | |
| GB201223187D0 (en) | Formula 1- 2050 | |
| GB201222981D0 (en) | Formula 1 -2050 | |
| GB201222964D0 (en) | Formula 1 - 2050 | |
| GB201207154D0 (en) | Novel form | |
| AU346613S (en) | Jewellery | |
| GB201222430D0 (en) | Novel compounds | |
| GB201222435D0 (en) | Novel compounds | |
| GB201222433D0 (en) | Novel compounds | |
| GB201222419D0 (en) | Novel compounds | |
| GB201222393D0 (en) | Novel compounds | |
| GB201219554D0 (en) | Novel compounds |